Surrozen (NASDAQ:SRZN) Trading 4.3% Higher – Here’s Why

Shares of Surrozen, Inc. (NASDAQ:SRZN) traded up 4.3% during trading on Tuesday . The company traded as high as $10.38 and last traded at $9.78. 41,869 shares changed hands during trading, an increase of 214% from the average session volume of 13,335 shares. The stock had previously closed at $9.38.

Surrozen Stock Performance

The business’s 50 day moving average is $9.59 and its 200 day moving average is $9.69.

Surrozen (NASDAQ:SRZN) last issued its earnings results on Monday, August 12th. The company reported ($1.54) EPS for the quarter, topping analysts’ consensus estimates of ($2.79) by $1.25. Analysts expect that Surrozen, Inc. will post -9.49 EPS for the current year.

Institutional Investors Weigh In On Surrozen

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC purchased a new stake in Surrozen in the second quarter valued at $2,080,000. Nantahala Capital Management LLC purchased a new stake in Surrozen in the second quarter valued at $2,050,000. Stonepine Capital Management LLC purchased a new stake in Surrozen in the second quarter valued at $724,000. Finally, CVI Holdings LLC purchased a new stake in Surrozen in the second quarter valued at $711,000. 66.57% of the stock is owned by hedge funds and other institutional investors.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.